Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Kuwait, United Arab Emirates and Qatar
Phase of Trial: Phase IV
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 19 Jun 2017 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned number of patients changed from 150 to 40.
- 08 May 2017 Planned End Date changed from 1 Mar 2017 to 7 Jun 2017.